Group 1 - L'Oréal has officially announced the acquisition of a majority stake in the UK skincare brand Medik8, which will be integrated into its luxury cosmetics division rather than its dermatological beauty division as previously speculated [1][2][3] - The acquisition is valued at approximately €1 billion (around 8.2 billion RMB), with the deal expected to be completed in the coming months pending regulatory approval [3][4] - Medik8's integration into L'Oréal's luxury cosmetics division highlights the company's focus on high-end scientific skincare and aims to expand Medik8's global market presence [1][4] Group 2 - Medik8, founded in 2009 by Elliot Isaacs, is known for its science-based skincare products and the "CSA" skincare philosophy, which emphasizes the use of Vitamin C during the day and Vitamin A at night [8][10] - Despite facing challenges in the Chinese market, Medik8 has shown strong global growth, with reported revenues of £45.3 million (approximately 440 million RMB) and a pre-tax profit of £15.6 million (around 150 million RMB) for the year ending September 2023 [18] - The brand's sales are projected to grow by 50% in 2024, and with L'Oréal's support, Medik8 is expected to enhance its research, distribution, and operational capabilities [18]